AstraZeneca: Japan grants orphan drug status to Lynparza
(CercleFinance.com) - AstraZeneca said on Thursday that Japanese regulators have granted orphan drug status to its Lynparza drug for the treatment of BRCA-mutated metastatic pancreatic cancer.
Pancreatic cancer has the lowest survival rate of the most common cancers and is the only major cancer with a five-year survival rate of below 10% in almost every country.
The Japanese Ministry of Health, Labour and Welfare grants orpahn drug designation to treatments of diseases that affect less than 50,000 patients in Japan, and for which there is a high unmet medical need.
Lynparza is co-developed and co-commercialised with US pharma giant Merck.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Pancreatic cancer has the lowest survival rate of the most common cancers and is the only major cancer with a five-year survival rate of below 10% in almost every country.
The Japanese Ministry of Health, Labour and Welfare grants orpahn drug designation to treatments of diseases that affect less than 50,000 patients in Japan, and for which there is a high unmet medical need.
Lynparza is co-developed and co-commercialised with US pharma giant Merck.
Copyright (c) 2020 CercleFinance.com. All rights reserved.